Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma

Risk Assessment for Newly Diagnosed Fit Young Patients with Multiple Myeloma in the Era of Novel Treatment Modalities: Should There Be Additional Factors Taken into Consideration??

“…In disagreement with other studies, we observed only slightly better OS for patients aged ≤55 years than those aged >55 years. 35,36 Possible explanations for this marginal OS superiority could be that the treatment protocols used were effective enough to get over the adverse impact of older age and that only 25% of our patients were older than 65 years. In the few studies designed for young patients, the only available data regarding the impact of novel agents on the outcome of younger patients come from studies with AHSCT-eligible patients.…”

“…However, looking at the opposite edge of the survival curves, the indisputable fact is that even for this favorable age-group, the probability of death within 4-5 years post-MM diagnosis is approximately 20%-30%. [35][36][37][38][39][40] In Ludwig et al study, autografted patients with aged <50 years demonstrated 4-year probability of death of approximately 30%. Nevertheless, it should be noted that patients were treated between 1981 and 2002 and thus novel triplet or quadruplet combinations were not in use.…”

Multiple Myeloma in a Young Adult

“…The time between initial presentation and final diagnosis is often extended because of the extreme rarity in younger patients, especially those younger than 30 years 3,5,9 . Finally, most studies agree that younger patients will have prolonged survival 3,4,[6][7][8] . However, an examination published in Annals of Hematology argues that the risk of death in patients younger than 50 years is higher when their expected mortality is considered 11 .…”

“…The use of autologous and allogeneic stem cell transplantation to treat younger patients is becoming increasingly popular because they seem to better withstand the therapy compared with older patients. 6-8…”

“…The use of autologous and allogeneic stem cell transplantation to treat younger patients is becoming increasingly popular because they seem to better withstand the therapy compared with older patients. [6][7][8] The patient we describe had a 1-year follow-up, was informed that data concerning the case would be submitted for publication, and he provided consent.…”